FDA Reports Inaccuracy in IQVIA Opioid Sales Data

May 16, 2018

(Reuters) – The U.S. Food & Drug Administration said on Wednesday it found inaccuracies in sales data of opioid drug products provided by IQVIA Holdings Inc, a vendor it contracts. The regulator said IQVIA overestimated past data on prescription opioid fentanyl due to an error in its weight-conversion methods, sending the shares of the company down as much as 10.3 percent to $91.57.